This year SAE's 3rd annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 11-12 September.

The only event that will:

Showcase new representation and insights from the following big pharma companies, with a high level agenda focussing on driving industry advancement, whilst also offering benchmarking and networking opportunities for leading figures in the industry.
- Eli lilly
- Moderna
- BioNTech
- Alnylam Pharmaceuticals
- GSK
- Merck
- Servier
- AstraZeneca
- Roche
- Bayer

What's different this year:

This year the conference will be chaired by two leaders in the field of oligonucleotide therapeutics and delivery: Joseph R. Martinelli, Executive Director, Genetic Medicine, Eli Lilly and Company and Edward Hennessy, Senior Director, Discovery Chemistry, Moderna.

Read on go.evvnt.com

Continue reading at smgconferences.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share